Discover investment opportunities in Catalyst Pharmaceuticals Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Catalyst Pharmaceuticals Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Catalyst Pharmaceuticals Stocks using our Smart AI Filter.
9 stocks found for "Catalyst Pharmaceuticals Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.70 Risk measure | ±46.8% Price volatility | 1.5 Valuation | 0.00% Annual yield | |||
0.62 Risk measure | ±41.3% Price volatility | -11.5 Valuation | 0.00% Annual yield | |||
1.21 Risk measure | ±56.0% Price volatility | -13.3 Valuation | 0.00% Annual yield | |||
0.30 Risk measure | ±26.0% Price volatility | 12.1 Valuation | 0.66% Annual yield | |||
0.47 Risk measure | ±33.4% Price volatility | 14.4 Valuation | 0.00% Annual yield | |||
0.90 Risk measure | ±63.6% Price volatility | -4.0 Valuation | 0.00% Annual yield | |||
0.36 Risk measure | ±26.9% Price volatility | 24.5 Valuation | 0.00% Annual yield | |||
1.95 Risk measure | ±75.5% Price volatility | -1.5 Valuation | 0.00% Annual yield | |||
0.34 Risk measure | ±25.2% Price volatility | 8.0 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
Read moreEylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
Read moreThe consensus price target hints at a 33.2% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read moreIonis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read morePTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read moreOn CNBC's 'Mad Money Lightning Round,' Jim Cramer recommended buying Dover Corporation DOV.
Read more